Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $450
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly maintains a Buy rating on Bio-Rad Laboratories and raises the price target from $400 to $450.

October 31, 2024 | 8:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Patrick Donnelly has reaffirmed a Buy rating for Bio-Rad Laboratories and increased the price target from $400 to $450, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and an increased price target from a major financial institution like Citigroup suggests a positive outlook for Bio-Rad Laboratories. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100